FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2221304580> ?p ?o ?g. }

• W2221304580 endingPage "587" @default.
• W2221304580 startingPage "580" @default.
• W2221304580 abstract "Purpose To determine the maximally tolerated dose of sorafenib delivered before, during, and after stereotactic body radiation therapy (SBRT) in hepatocellular carinoma (HCC). Methods and Materials Eligible patients had locally advanced Child-Pugh class A HCC, showed Eastern Cooperative Oncology Group performance status 0-1, and were ineligible for standard local-regional therapies. Sorafenib was dose escalated in 2 strata: (1) low effective irradiated liver volume (veff) < 30% and (2) high veff 30%to 60%. Sorafenib (400 mg daily = dose level 1) was administered for 12 weeks, with 6 fractions SBRT delivered weeks 2 and 3, and escalation to full dose (400 mg twice daily) after 12 weeks as tolerated. Standard 3 + 3 cohorts with dose escalation of sorafenib were planned. Results Sixteen patients (4 low veff, median dose 51 Gy; 12 high veff, median dose 33 Gy) were treated at 2 sorafenib dose levels. Of those patients 75% were had Barcelona Clinic Liver Cancer stage C, and 63% had main branch portal vein invasion. In the low veff stratum, no dose-limiting toxicities (DLTs) were observed in 4 patients treated with SBRT and sorafenib 400 mg. Inb the high veff stratum: 2 of 3 evaluable patients treated with sorafenib 400 mg experienced DLT (grade 3 large bowel bleed and grade 4 bowel obstruction 51 and 27 days, respectively, after SBRT). One of 6 evaluable patients at dose level −1 (200 mg once daily) experienced a grade 3 tumor rupture at week 5. Median overall survival and in-field local progression have not been reached. Worsening of Child-Pugh liver function class was seen in 6 of 12 patients in the high veff stratum. Conclusions Significant toxicity was observed in the high veff stratum, and concurrent SBRT with sorafenib is not recommended outside a clinical trial. To determine the maximally tolerated dose of sorafenib delivered before, during, and after stereotactic body radiation therapy (SBRT) in hepatocellular carinoma (HCC). Eligible patients had locally advanced Child-Pugh class A HCC, showed Eastern Cooperative Oncology Group performance status 0-1, and were ineligible for standard local-regional therapies. Sorafenib was dose escalated in 2 strata: (1) low effective irradiated liver volume (veff) < 30% and (2) high veff 30%to 60%. Sorafenib (400 mg daily = dose level 1) was administered for 12 weeks, with 6 fractions SBRT delivered weeks 2 and 3, and escalation to full dose (400 mg twice daily) after 12 weeks as tolerated. Standard 3 + 3 cohorts with dose escalation of sorafenib were planned. Sixteen patients (4 low veff, median dose 51 Gy; 12 high veff, median dose 33 Gy) were treated at 2 sorafenib dose levels. Of those patients 75% were had Barcelona Clinic Liver Cancer stage C, and 63% had main branch portal vein invasion. In the low veff stratum, no dose-limiting toxicities (DLTs) were observed in 4 patients treated with SBRT and sorafenib 400 mg. Inb the high veff stratum: 2 of 3 evaluable patients treated with sorafenib 400 mg experienced DLT (grade 3 large bowel bleed and grade 4 bowel obstruction 51 and 27 days, respectively, after SBRT). One of 6 evaluable patients at dose level −1 (200 mg once daily) experienced a grade 3 tumor rupture at week 5. Median overall survival and in-field local progression have not been reached. Worsening of Child-Pugh liver function class was seen in 6 of 12 patients in the high veff stratum. Significant toxicity was observed in the high veff stratum, and concurrent SBRT with sorafenib is not recommended outside a clinical trial." @default.
• W2221304580 created "2016-06-24" @default.
• W2221304580 creator A5002961136 @default.
• W2221304580 creator A5005287001 @default.
• W2221304580 creator A5017277973 @default.
• W2221304580 creator A5019086649 @default.
• W2221304580 creator A5032753703 @default.
• W2221304580 creator A5037659354 @default.
• W2221304580 creator A5048005267 @default.
• W2221304580 creator A5057674768 @default.
• W2221304580 creator A5068644454 @default.
• W2221304580 creator A5080668859 @default.
• W2221304580 date "2016-03-01" @default.
• W2221304580 modified "2023-10-17" @default.
• W2221304580 title "Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma" @default.
• W2221304580 cites W1969790467 @default.
• W2221304580 cites W1971837077 @default.
• W2221304580 cites W1976228480 @default.
• W2221304580 cites W1981783305 @default.
• W2221304580 cites W1985541438 @default.
• W2221304580 cites W2015472953 @default.
• W2221304580 cites W2022590769 @default.
• W2221304580 cites W2055240846 @default.
• W2221304580 cites W2085871700 @default.
• W2221304580 cites W2099165212 @default.
• W2221304580 cites W2113248775 @default.
• W2221304580 cites W2114334138 @default.
• W2221304580 cites W2126453212 @default.
• W2221304580 cites W2133685049 @default.
• W2221304580 cites W2144284656 @default.
• W2221304580 cites W2169961966 @default.
• W2221304580 cites W2171500698 @default.
• W2221304580 doi "https://doi.org/10.1016/j.ijrobp.2015.11.048" @default.
• W2221304580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26867886" @default.
• W2221304580 hasPublicationYear "2016" @default.
• W2221304580 type Work @default.
• W2221304580 sameAs 2221304580 @default.
• W2221304580 citedByCount "91" @default.
• W2221304580 countsByYear W22213045802016 @default.
• W2221304580 countsByYear W22213045802017 @default.
• W2221304580 countsByYear W22213045802018 @default.
• W2221304580 countsByYear W22213045802019 @default.
• W2221304580 countsByYear W22213045802020 @default.
• W2221304580 countsByYear W22213045802021 @default.
• W2221304580 countsByYear W22213045802022 @default.
• W2221304580 countsByYear W22213045802023 @default.
• W2221304580 crossrefType "journal-article" @default.
• W2221304580 hasAuthorship W2221304580A5002961136 @default.
• W2221304580 hasAuthorship W2221304580A5005287001 @default.
• W2221304580 hasAuthorship W2221304580A5017277973 @default.
• W2221304580 hasAuthorship W2221304580A5019086649 @default.
• W2221304580 hasAuthorship W2221304580A5032753703 @default.
• W2221304580 hasAuthorship W2221304580A5037659354 @default.
• W2221304580 hasAuthorship W2221304580A5048005267 @default.
• W2221304580 hasAuthorship W2221304580A5057674768 @default.
• W2221304580 hasAuthorship W2221304580A5068644454 @default.
• W2221304580 hasAuthorship W2221304580A5080668859 @default.
• W2221304580 hasConcept C126322002 @default.
• W2221304580 hasConcept C143998085 @default.
• W2221304580 hasConcept C2776231280 @default.
• W2221304580 hasConcept C2778019345 @default.
• W2221304580 hasConcept C2778695046 @default.
• W2221304580 hasConcept C2989005 @default.
• W2221304580 hasConcept C509974204 @default.
• W2221304580 hasConcept C71924100 @default.
• W2221304580 hasConcept C90924648 @default.
• W2221304580 hasConceptScore W2221304580C126322002 @default.
• W2221304580 hasConceptScore W2221304580C143998085 @default.
• W2221304580 hasConceptScore W2221304580C2776231280 @default.
• W2221304580 hasConceptScore W2221304580C2778019345 @default.
• W2221304580 hasConceptScore W2221304580C2778695046 @default.
• W2221304580 hasConceptScore W2221304580C2989005 @default.
• W2221304580 hasConceptScore W2221304580C509974204 @default.
• W2221304580 hasConceptScore W2221304580C71924100 @default.
• W2221304580 hasConceptScore W2221304580C90924648 @default.
• W2221304580 hasIssue "3" @default.
• W2221304580 hasLocation W22213045801 @default.
• W2221304580 hasLocation W22213045802 @default.
• W2221304580 hasOpenAccess W2221304580 @default.
• W2221304580 hasPrimaryLocation W22213045801 @default.
• W2221304580 hasRelatedWork W1970460092 @default.
• W2221304580 hasRelatedWork W2034139851 @default.
• W2221304580 hasRelatedWork W2087356637 @default.
• W2221304580 hasRelatedWork W2280419820 @default.
• W2221304580 hasRelatedWork W2415536161 @default.
• W2221304580 hasRelatedWork W2769323635 @default.
• W2221304580 hasRelatedWork W3018861914 @default.
• W2221304580 hasRelatedWork W4285206599 @default.
• W2221304580 hasRelatedWork W4361816912 @default.
• W2221304580 hasRelatedWork W4362622788 @default.
• W2221304580 hasVolume "94" @default.
• W2221304580 isParatext "false" @default.
• W2221304580 isRetracted "false" @default.
• W2221304580 magId "2221304580" @default.
• W2221304580 workType "article" @default.